Comments
Strides Pharma Science on Thursday announced that its step-down wholly-owned subsidiary, Strides Pharma Global Pte Limited, Singapore, has received approval for Loratadine Softgel Capsules, 10-mg (OTC) from the United States Food & Drug Administration. Loratadine softgel capsule is part of Strides’ niche and small volume product portfolio with limited competition in the US private label market. According to IRi data, the US market for the drug is approximately $50 million with only one other generic approval. The product will be manufactured at the company’s oral dosage facility at Bengaluru. The stock closed 0.62 per cent lower at ₹387.20 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.